+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Blood Cancer Therapeutics Market 2019-2023 - Product Image

Global Blood Cancer Therapeutics Market 2019-2023

  • ID: 4760033
  • Report
  • February 2019
  • Region: Global
  • 119 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • MORE
Leukemia is the most common type of cancer in children and also accounts for the highest mortality rate among cancers in pediatric patients. The prevalence of leukemia has been increasing at a significantly high rate.

The incidence of other types of blood cancer such as lymphomas is also another factor driving the growth of the market, as it is leading to vendors conducting research on new areas. Most of the drugs are being developed for both lymphoma and leukemia, thus leading to more vendors entering the market to research on novel therapies. The high incidence of various types of leukemia in pediatric patients is expected to be one of the major drivers of the global blood cancer therapeutics market during the forecast period. The analysts have predicted that the blood cancer therapeutics market will register CAGR of over 8% by 2023.

Market Overview

Growing adoption of therapeutics

The increasing awareness about the disease, along with the increasing global incidence, is leading to more patients undergoing diagnosis and opting for treatment during the early stages of the disease. This is leading to the increasing adoption of therapeutics for the treatment. These factors are expected to result in the growth of the global blood cancer therapeutics market during the forecast period.

Adverse effects of stem cell transplantation

Bone marrow and stem cell transplantations are some of the most effective treatment options for the treatment of blood cancer types such as leukemia, multiple myeloma, and non-Hodgkin's lymphoma. Although the treatment using stem cells is highly effective for the treatment of cancer, the side effects associated with the treatment are often high. The threat of side effects of stem cell transplant is expected to continue posing a challenge to the market growth during the forecast period.

For the detailed list of factors that will drive and challenge the growth of the blood cancer therapeutics market during the 2019-2023, view this report.

Competitive Landscape

The market appears to be fairly fragmented and with the presence of several vendors. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 06: PIPELINE

PART 07: MARKET SEGMENTATION BY TYPE
  • Market segmentation by type
  • Comparison by type
  • Leukemia - Market size and forecast 2018-2023
  • Lymphoma - Market size and forecast 2018-2023
  • Myeloma - Market size and forecast 2018-2023
  • Market opportunity by type
PART 08: CUSTOMER LANDSCAPE

PART 09: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 12: MARKET TRENDS

PART 13: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
  • Competitive scenario
PART 14: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd
  • Johnson & Johnson Services, Inc.
  • Novartis AG
  • Takeda Pharmaceutical Company Limited
PART 15: APPENDIX
  • Research methodology
  • List of abbreviations
List of Exhibits
Exhibit 01: Global oncology therapeutics market
Exhibit 02: Segments of global oncology therapeutics market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Global blood cancer therapeutics market pipeline: Overview
Exhibit 18: Global blood cancer therapeutics market pipeline: Overview
Exhibit 19: Type - Market share 2018-2023 (%)
Exhibit 20: Comparison by type
Exhibit 21: Leukemia - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Leukemia - Year-over-year growth 2019-2023 (%)
Exhibit 23: Lymphoma - Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Lymphoma - Year-over-year growth 2019-2023 (%)
Exhibit 25: Myeloma - Market size and forecast 2018-2023 ($ millions)
Exhibit 26: Myeloma - Year-over-year growth 2019-2023 (%)
Exhibit 27: Market opportunity by type
Exhibit 28: Customer landscape
Exhibit 29: Market share by geography 2018-2023 (%)
Exhibit 30: Geographic comparison
Exhibit 31: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: North America - Year-over-year growth 2019-2023 (%)
Exhibit 33: Top 3 countries in North America
Exhibit 34: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 35: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 36: Top 3 countries in Europe
Exhibit 37: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 38: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 39: Top 3 countries in Asia
Exhibit 40: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 41: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 42: Top 3 countries in ROW
Exhibit 43: Key leading countries
Exhibit 44: Market opportunity
Exhibit 45: Impact of drivers and challenges
Exhibit 46: Vendor landscape
Exhibit 47: Landscape disruption
Exhibit 48: Vendors covered
Exhibit 49: Vendor classification
Exhibit 50: Market positioning of vendors
Exhibit 51: Bristol-Myers Squibb Company - Vendor overview
Exhibit 52: Bristol-Myers Squibb Company - Business segments
Exhibit 53: Bristol-Myers Squibb Company - Organizational developments
Exhibit 54: Bristol-Myers Squibb Company - Geographic focus
Exhibit 55: Bristol-Myers Squibb Company - Key offerings
Exhibit 56: Bristol-Myers Squibb Company - Key customers
Exhibit 57: F. Hoffmann-La Roche Ltd - Vendor overview
Exhibit 58: F. Hoffmann-La Roche Ltd - Business segments
Exhibit 59: F. Hoffmann-La Roche Ltd - Organizational developments
Exhibit 60: F. Hoffmann-La Roche Ltd - Geographic focus
Exhibit 61: F. Hoffmann-La Roche Ltd - Segment focus
Exhibit 62: F. Hoffmann-La Roche Ltd - Key offerings
Exhibit 63: F. Hoffmann-La Roche Ltd - Key customers
Exhibit 64: Johnson & Johnson Services, Inc. - Vendor overview
Exhibit 65: Johnson & Johnson Services, Inc. - Business segments
Exhibit 66: Johnson & Johnson Services, Inc. - Organizational developments
Exhibit 67: Johnson & Johnson Services, Inc. - Geographic focus
Exhibit 68: Johnson & Johnson Services, Inc. - Segment focus
Exhibit 69: Johnson & Johnson Services, Inc. - Key offerings
Exhibit 70: Johnson & Johnson Services, Inc. - Key customers
Exhibit 71: Novartis AG - Vendor overview
Exhibit 72: Novartis AG - Business segments
Exhibit 73: Novartis AG - Organizational developments
Exhibit 74: Novartis AG - Geographic focus
Exhibit 75: Novartis AG - Segment focus
Exhibit 76: Novartis AG - Key offerings
Exhibit 77: Novartis AG - Key customers
Exhibit 78: Takeda Pharmaceutical Company Limited - Vendor overview
Exhibit 79: Takeda Pharmaceutical Company Limited - Business segments
Exhibit 80: Takeda Pharmaceutical Company Limited - Organizational developments
Exhibit 81: Takeda Pharmaceutical Company Limited - Geographic focus
Exhibit 82: Takeda Pharmaceutical Company Limited - Key offerings
Exhibit 83: Takeda Pharmaceutical Company Limited - Key customers
Exhibit 84: Validation techniques employed for market sizing
Note: Product cover images may vary from those shown
3 of 5

FEATURED COMPANIES

  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • MORE
Global Blood Cancer Therapeutics Market 2019-2023

The analyst recognizes the following companies as the key players in the global blood cancer therapeutics market: Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Johnson & Johnson Services, Inc., Novartis AG, Takeda Pharmaceutical Company Limited.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the increasing research grants for developing therapies for blood cancer has increased significantly and such investments are expected to contribute to the growth.”

According to the report, one of the major drivers for this market is the rapidly increasing investments in the construction and utilities industries across the advanced and emerging economies.

Further, the report states that one of the major factors hindering the growth of this market is the increase in number of trail failures is expected to pose a major threat to the growth of the market during our forecast period.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
4 of 5
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd
  • Johnson & Johnson Services, Inc.
  • Novartis AG
  • Takeda Pharmaceutical Company Limited
Note: Product cover images may vary from those shown
5 of 5

Loading
LOADING...

Adroll
adroll